- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07607379
Robotic Dog Intervention on Emotional Well-Being and Quality of Life (ROBDOG)
Effectiveness and Feasibility of a Robotic Dog Intervention on Emotional Well-Being and Quality of Life in Pediatric Patients With Hematological Malignancies Undergoing HSCT
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) experience substantial psychological burden related to intensive treatment, protective isolation, prolonged hospitalization, and immunosuppression. Anxiety, emotional distress, loneliness, and reduced quality of life are common during the post-transplant inpatient period. However, infection control precautions and isolation procedures may limit access to traditional psychosocial support interventions in HSCT settings.
Technology-assisted interventions, particularly social robots, have emerged as promising approaches for supporting emotional well-being in pediatric healthcare environments. AI-powered robotic companion devices may provide interactive engagement, emotional comfort, and opportunities for play during prolonged hospitalization while remaining compatible with infection control requirements.
This pilot randomized controlled study aims to evaluate the effectiveness, feasibility, and acceptability of an AI-powered robotic dog intervention in improving emotional well-being and quality of life in pediatric patients undergoing HSCT.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Eysan Savaş, PhD
- Número de telefone: +90 5068418841
- E-mail: eysansavas@gmail.com
Estude backup de contato
- Nome: Remziye Semerci, PhD
- Número de telefone: +90 535 0112821
- E-mail: remziyesemerci@gmail.com
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Pediatric patients aged 8-15 years
- Diagnosed with a hematological malignancy and undergoing hematopoietic stem cell transplantation
- Hospitalized in a protective isolation room during the post-transplant inpatient period
- Expected to remain hospitalized under isolation for approximately 30 days post-transplant
- Able to understand and respond to Turkish-language self-report questionnaires
- Clinically stable and deemed eligible for participation by the treating clinical team
- Able to interact with the robotic dog at a basic functional level
Exclusion Criteria:
- Severe cognitive impairment or neurodevelopmental conditions preventing meaningful interaction or self-report
- Acute neurological conditions, delirium, or severe psychiatric crisis (e.g., acute agitation, suicidal ideation)
- Requirement for intensive care, invasive ventilation, or a clinically unstable condition
- Severe visual, hearing, or motor impairments that prevent interaction with the robotic dog
- Additional infection control restrictions prevent the placement or use of the robotic dog in the isolation room
- Anticipated early discharge, transfer, or inability to complete follow-up assessments
- Severe fear, intolerance, or refusal to interact with robotic or electronic devices
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Standard care & Control Group Care
Participants in the control group will receive standard post-transplant inpatient care routinely provided in the HSCT unit.
Standard care includes protective isolation procedures, restricted visitor access, routine clinical monitoring, and infection control practices during the inpatient transplantation period.
Children are permitted to use personal electronic devices and other approved washable or disinfectable materials available within institutional infection control regulations.
No structured psychosocial or technology-assisted intervention will be provided to the control group during the study period.
|
|
|
Experimental: Intervention Group (AIBO Group):
Participants assigned to the intervention group will receive standard post-transplant inpatient care in addition to a technology-assisted psychosocial support intervention during the inpatient isolation period following HSCT.
The intervention will be implemented throughout the hospitalization period, and participants will be encouraged to engage with the device regularly during daily care routines.
Baseline assessments will be performed within the first 24-48 hours after HSCT, and follow-up assessments will be conducted weekly for four weeks.
Intervention adherence, feasibility indicators, and adverse events will be monitored throughout the study period.
Infection control procedures will be applied according to institutional protocols.
|
AIBO is an AI-powered interactive robot dog that engages children through play and touch-based interactions, including responding to petting, interacting with a ball, and making simple gestures.
Using visual, auditory, and tactile sensing, AIBO enables spontaneous, child-centered interactions, expressing emotions through eye color changes, tail movements, and vocalizations, while gradually developing more adaptive behaviors through repeated interactions (weight: ~2.2 kg; dimensions: 180 × 293 × 305 mm)
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Positive and Negative Affect
Prazo: Baseline (Day 1, before intervention initiation) and weekly assessments during the intervention period at Weeks 2, 3, and 4.
|
Emotional affect will be assessed using the Positive and Negative Affect Schedule for Children (PANAS-C).
The scale evaluates positive and negative emotional states experienced by pediatric patients undergoing hematopoietic stem cell transplantation during the inpatient isolation period.
|
Baseline (Day 1, before intervention initiation) and weekly assessments during the intervention period at Weeks 2, 3, and 4.
|
|
Change in Emotional Well-being
Prazo: Baseline (Day 1, before intervention initiation) and weekly assessments during the intervention period at Weeks 2, 3, and 4.
|
Children's emotional well-being will be assessed using the Stirling Children's Well-being Scale.
The scale evaluates positive emotional functioning, interpersonal relationships, and overall psychological well-being in children undergoing hematopoietic stem cell transplantation during the inpatient isolation period.
|
Baseline (Day 1, before intervention initiation) and weekly assessments during the intervention period at Weeks 2, 3, and 4.
|
|
Change in Health-Related Quality of Life
Prazo: Baseline (Day 1, prior to intervention initiation) and Week 4 (post-intervention assessment after completion of the 4-week intervention period).
|
Health-related quality of life will be assessed using the Pediatric Quality of Life Inventory (PedsQL 4.0).
The scale consists of 23 items evaluating physical, emotional, social, and school functioning in children and adolescents.
Items are rated on a 5-point Likert scale, with higher scores indicating better health-related quality of life.
|
Baseline (Day 1, prior to intervention initiation) and Week 4 (post-intervention assessment after completion of the 4-week intervention period).
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- KOCUNIVR
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .